Clinical stage drug maker Lynk Pharmaceuticals Co. has completed a Series B round of financing, raising as much as $50 million, led by the Shanghai-based venture capital firm Lilly Asia Ventures (LAV), the investor announced on Friday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
